{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:09:43Z","timestamp":1791202183817,"version":"4.2.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T00:00:00Z","timestamp":1412640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T00:00:00Z","timestamp":1412640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/tpj.2014.49","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T10:00:00Z","timestamp":1412676000000},"page":"144-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients"],"prefix":"10.1038","volume":"15","author":[{"given":"H","family":"de Jonge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Elens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"de Loor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R H","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D R J","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,7]]},"reference":[{"key":"BFtpj201449_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","volume":"31","author":"H de Jonge","year":"2009","unstructured":"de Jonge H, Naesens M, Kuypers DR . New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31: 416\u2013435.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201449_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE . Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623\u2013653.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj201449_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1124\/dmd.105.008680","volume":"34","author":"Y Dai","year":"2006","unstructured":"Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836\u2013847.","journal-title":"Drug Metab Dispos"},{"key":"BFtpj201449_CR4","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","volume":"51","author":"LK Kamdem","year":"2005","unstructured":"Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 2005; 51: 1374\u20131381.","journal-title":"Clin Chem"},{"key":"BFtpj201449_CR5","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","volume":"268","author":"T Saeki","year":"1993","unstructured":"Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T . Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077\u20136080.","journal-title":"J Biol Chem"},{"key":"BFtpj201449_CR6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG, Thummel KE . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271\u20131294.","journal-title":"Adv Drug Deliv Rev"},{"key":"BFtpj201449_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/mol.62.1.162","volume":"62","author":"YS Lin","year":"2002","unstructured":"Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162\u2013172.","journal-title":"Mol Pharmacol"},{"key":"BFtpj201449_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trre.2007.09.002","volume":"22","author":"H de Jonge","year":"2008","unstructured":"de Jonge H, Kuypers DR . Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando) 2008; 22: 6\u201320.","journal-title":"Transplant Rev (Orlando)"},{"key":"BFtpj201449_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","volume":"53","author":"DA Hesselink","year":"2013","unstructured":"Hesselink DA, Bouamar R, Elens L, van Schaik RH, van GT . The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2013; 53: 123\u2013139.","journal-title":"Clin Pharmacokinet"},{"key":"BFtpj201449_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245\u2013254.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201449_CR11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1097\/00007890-200212150-00002","volume":"74","author":"IA MacPhee","year":"2002","unstructured":"MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486\u20131489.","journal-title":"Transplantation"},{"key":"BFtpj201449_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/TP.0b013e318200e991","volume":"91","author":"PA Jacobson","year":"2011","unstructured":"Jacobson PA, Oetting WS, Brearley AM, Leduc R, Guan W, Schladt D et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011; 91: 300\u2013308.","journal-title":"Transplantation"},{"key":"BFtpj201449_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2217\/pgs.11.90","volume":"12","author":"L Elens","year":"2011","unstructured":"Elens L, van Schaik RH, Panin N, De MM, Wallemacq P, Lison D et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011; 12: 1383\u20131396.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201449_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","volume":"57","author":"L Elens","year":"2011","unstructured":"Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van GT et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011; 57: 1574\u20131583.","journal-title":"Clin Chem"},{"key":"BFtpj201449_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/FPC.0b013e3283636856","volume":"23","author":"B Tavira","year":"2013","unstructured":"Tavira B, Coto E, Diaz-Corte C, Alvarez V, Lopez-Larrea C, Ortega F . A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenet Genomics 2013; 23: 445\u2013448.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201449_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","volume":"70","author":"I Lunde","year":"2014","unstructured":"Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 2014; 70: 685\u2013693.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtpj201449_CR17","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1038\/psp.2013.78","volume":"3","author":"DJ Moes","year":"2014","unstructured":"Moes DJ, Swen JJ, den HJ, van der Straaten T, van der Heide JJ, Sanders JS et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. CPT Pharmacometrics Syst Pharmacol 2014; 3: e100.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"BFtpj201449_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/clpt.2013.68","volume":"94","author":"AB Santoro","year":"2013","unstructured":"Santoro AB, Struchiner CJ, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Suarez-Kurtz G . CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin Pharmacol Ther 2013; 94: 201\u2013202.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201449_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W . Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11: 274\u2013286.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201449_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2131\/jts.38.349","volume":"38","author":"M Okubo","year":"2013","unstructured":"Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H . CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci 2013; 38: 349\u2013354.","journal-title":"J Toxicol Sci"},{"key":"BFtpj201449_CR21","first-page":"37","volume":"14","author":"L Elens","year":"2013","unstructured":"Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V et al. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 2013; 14: 37\u201349.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201449_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.2217\/pgs.13.133","volume":"14","author":"H de Jonge","year":"2013","unstructured":"de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR . Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Pharmacogenomics 2013; 14: 1467\u20131480.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201449_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/clpt.2012.109","volume":"92","author":"H de Jonge","year":"2012","unstructured":"de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR . In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 2012; 92: 366\u2013375.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201449_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2011.130","volume":"90","author":"H de Jonge","year":"2011","unstructured":"de Jonge H, e Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR . In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clin Pharmacol Ther 2011; 90: 414\u2013422.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201449_CR25","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller SA, Dykes DD, Polesky HF . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.","journal-title":"Nucleic Acids Res"},{"key":"BFtpj201449_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/bmc.1576","volume":"25","author":"H de Loor","year":"2011","unstructured":"de Loor H, de Jonge H, Verbeke K, Vanrenterghem Y, Kuypers DR . A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. Biomed Chromatogr 2011; 25: 1091\u20131098.","journal-title":"Biomed Chromatogr"},{"key":"BFtpj201449_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.clinbiochem.2010.03.016","volume":"43","author":"KL Napoli","year":"2010","unstructured":"Napoli KL, Hammett-Stabler C, Taylor PJ, Lowe W, Franklin ME, Morris MR et al. Multi-center evaluation of a commercial Kit for tacrolimus determination by LC\/MS\/MS. Clin Biochem 2010; 43: 910\u2013920.","journal-title":"Clin Biochem"},{"key":"BFtpj201449_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/1471-2105-8-428","volume":"8","author":"TR Gaunt","year":"2007","unstructured":"Gaunt TR, Rodriguez S, Day IN . Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 2007; 8: 428.","journal-title":"BMC Bioinformatics"},{"key":"BFtpj201449_CR29","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/FTD.0b013e318296045b","volume":"35","author":"L Elens","year":"2013","unstructured":"Elens L, Capron A, van Schaik RH, De MM, De PL, Eddour DC et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit 2013; 35: 608\u2013616.","journal-title":"Ther Drug Monit"},{"key":"BFtpj201449_CR30","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/tri.12194","volume":"26","author":"A Asberg","year":"2013","unstructured":"Asberg A, Midtvedt K, van GM, Storset E, Bremer S, Bergan S et al. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int 2013; 26: 1198\u20131207.","journal-title":"Transpl Int"},{"key":"BFtpj201449_CR31","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1093\/ndt\/gfg381","volume":"18","author":"D Anglicheau","year":"2003","unstructured":"Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409\u20132414.","journal-title":"Nephrol Dial Transplant"},{"key":"BFtpj201449_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1097\/00007890-200211270-00014","volume":"74","author":"T Shimada","year":"2002","unstructured":"Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002; 74: 1419\u20131424.","journal-title":"Transplantation"},{"key":"BFtpj201449_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00147-003-0615-1","volume":"16","author":"EM van Duijnhoven","year":"2003","unstructured":"van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP . Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16: 721\u2013725.","journal-title":"Transpl Int"},{"key":"BFtpj201449_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","volume":"82","author":"DR Kuypers","year":"2007","unstructured":"Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y . CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711\u2013725.","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201449","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:05:09Z","timestamp":1647943509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,7]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFtpj201449"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2014.49","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,7]]},"assertion":[{"value":"13 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}